Mechanisms of Calcineurin Inhibitor Nephrotoxicity in Chronic Allograft Injury

Slattery, Craig; Cassidy, Hilary; Johnston, Olwyn; Ryan, Michael P.; McMorrow, Tara

doi:10.5772/25778

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

2023

Publication Types

Select...

Article2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 101 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the first successful kidney transplant in 1954, kidney transplantation has become the routine management for patients presenting with end‐stage renal disease (ESRD) . The two most common causes of long‐term graft loss remain “death with a functioning graft,” usually from a marked excess of cardiovascular mortality in allograft recipients, and chronic allograft nephropathy (CAN) , the term given to the development of fibrotic processes leading to progressive allograft dysfunction with variable proteinuria and hypertension .…”

Section: Introductionmentioning

confidence: 99%

Urinary biomarkers of chronic allograft nephropathy

Cassidy

Slyne

O’Kelly

et al. 2015

Proteomics Clinical Apps

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Urinary biomarkers of chronic allograft nephropathy

Cassidy

Slyne

O’Kelly

et al. 2015

Proteomics Clinical Apps

Self Cite

View full text Add to dashboard Cite

show abstract

Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis

Atluri¹,

Manne²,

Nalamothu³

et al. 2023

Crit Rev Ther Drug Carrier Syst

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a complex pathophysiology. Treatment of AD remains challenging owing to the presence of a wide spectrum of clinical phenotypes and limited response to existing therapies. However, recent genetic, immunological, and pathophysiological insights into the disease mechanism resulted in the invention of novel therapeutic drug candidates. This review provides a comprehensive overview of current therapies and assesses various novel drug delivery strategies currently under clinical investigation. Further, this review majorly emphasizes on various topical treatments including emollient therapies, barrier repair agents, topical corticosteroids (TCS), phosphodiesterase 4 (PDE4) inhibitors, calcineurin inhibitors, and Janus kinase (<i>JAK</i>)-signal transducer and activator of transcription (<i>STAT</i>) pathway inhibitors. It also discusses biological and systemic therapies, upcoming treatments based on ongoing clinical trials. Additionally, this review scrutinized the use of pharmaceutical inactive ingredients in the approved topical dosage forms for AD treatment.

show abstract

Mechanisms of Calcineurin Inhibitor Nephrotoxicity in Chronic Allograft Injury

Cited by 2 publications

References 101 publications

Urinary biomarkers of chronic allograft nephropathy

Urinary biomarkers of chronic allograft nephropathy

Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis

Contact Info

Product

Resources

About